General Partner

• WSJ 2025 — Most Influential Corporate Directors
• Current Board of Directors at Alphabet, Corning, Klarna, and IFF
• Current Partner and Chief Investment Officer, Red Cell Partners
• Former CEO of TIAA (Fortune 100 firm managing >$1 Trillion in AUM)
• Former Vice-Chairman of the Federal Reserve Board of Governors (led the Fed’s initial financial response to 9/11)
• Former Head of Financial Services for Swiss Re & Former Partner at McKinsey & Company
• Served on President Obama’s Council on Jobs and Competitiveness
• BA, JD, and PhD in Economics — Harvard University

General Partner

• Former Operator and specialist in growth-stage investing & scaling ventures
• Co-founder EquiLend, largest trading platform in securities lending, with >$25Bn in transactions daily
• Invested >$350m and advised on >$15b of transactions into venture and growth companies
• Best-in-class DPI (1.1x) and TVPI (>2.5x) on growth-stage capital invested (2019 vintage)
• Venture partner at Archer Capital
• Multiple board or operator roles throughout — BlueFin, JOOR, Trilogy Education, & AMEX Global Travel

General Partner

• Business Insider 2025 — Top 100 Early-Stage Investor
• Neuroscientist & Co-founder, Revalia Bio
• Current External Advisor to Amgen & Board Member at Critical Path Institute
• Led 70 early-stage investments at BoxOne Ventures and Former Venture Partner at Entrepreneur First
• Invested in over 100 startups with >$10b in enterprise value
• Former EIR supporting ARPA-H contracts ($1.5b)
• Former operator and advisor at Accenture, Absci, bit.bio, Numerate, Mekonos, and AstraZeneca
• Former Visiting Scholar at the Wyss Institute, Harvard Medical School

Venture Partner

• Co-Founder and former CEO, TwinStrand Biosciences
• Developer of ultra-high accuracy Duplex Sequencing technology
• Attending oncologist, VA Puget Sound healthcare system
• Clinical Professor of Hematology and Oncology, University of Washington
• MD, PhD — University of Washington

Venture Partner

• Forbes — 10 Women Leading the Synthetic Biology Revolution
• Independent Director, Alexandria Real Estate Equities (NYSE: ARE)
• Scientific Advisory Board, Colossal Biosciences Inc.
• Former Chief Strategy Officer, Form Bio & VP at Remeditex Ventures
• PhD in Immunology and Genetics — Duke University

Venture Partner

• Serial life sciences Founder and CEO
• Professor of Transplantation, University of Cambridge
• Chief Medical Officer, Oxford Immune Algorithmics
• Co-founder & CSO, Revalia Bio
• MD, PhD in Neurosciences — University of Cambridge

Venture Partner

• TED Senior Fellow & Fellow of the Royal Society of Biology
• Co-founder and CSO, Spiderwort Inc.
• Former Full Professor of Biophysics and Canada Research Chair, University of Ottawa
• Renowned biophysicist and trailblazer in regenerative medicine
• PhD — UCLA

Venture Partner

• CEO, Vanna Health & Co-author of Bench, Bedside, Boardroom
• Former Deputy Chief Clinical Officer, Anthem & CMO at Everly Health
• Founded multiple venture-backed digital health companies
• Practicing Physician and Faculty, Harvard Medical School
• MD from Harvard, MBA from Harvard Business School, BA from Stanford

Venture Partner

• Serial venture creator with 30+ years of biopharma & tech experience
• Former Chairman & CEO of Xybion Digital (led landmark 40X+ MOIC exit)
• Former Founding Managing Partner at Accenture (scaled Life Sciences R&D unit to $1B)
• Public Company Chairman and seasoned board director
• PhD in Pharmaceutical Sciences — University of Wisconsin-Madison; MBA — The Wharton School

Venture Partner

• Forbes 30 Under 30 honoree
• CEO and co-founder, GreenCat
• Serial Founder, Entrepreneur, and former international corporate attorney in NYC
• Visiting Scholar/Fellow at Harvard Law School & Columbia Law School
• Masters from University of Cambridge; UC Berkeley School of Law